Qingcai Meng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qingcai Meng has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Chen Liang
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
5 shared publications - Jin Xu
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
5 shared publications - Xianjun Yu
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Pancreatic Cancer Institute, Shanghai 200032, China; Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China
5 shared publications - Zhen Tan
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
5 shared publications - Bo Zhang
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
4 shared publications - Jiang Liu
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
4 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression
Supplementary Materials and methods Supplementary Figures S1 to S17 Supplementary Tables S1 to S7
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression
Supplementary Materials and methods Supplementary Figures S1 to S17 Supplementary Tables S1 to S7
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal tumor with limited treatment options and poor patient survival. Circular RNAs (circRNA) play crucial regulatory roles in the occurrence and development of various cancers, including PDAC. In this study, using circRNA sequencing of diverse PDAC samples, we identified circRREB1 as an oncogenic circRNA that is significantly upregulated in PDAC and is correlated with an unfavorable patient prognosis. Functionally, loss of circRREB1 markedly inhibited glycolysis and stemness, whereas elevated circRREB1 elicited the opposite effects. Mechanistically, circRREB1 interacted with PGK1, disrupting the association between PTEN and PGK1 and increasing PGK1 phosphorylation to activate glycolytic flux. Moreover, circRREB1 promoted WNT7B transcription by directly interacting with YBX1 and facilitating its nuclear translocation, consequently activating the Wnt/β-catenin signaling pathway to maintain PDAC stemness. Overall, these results highlight circRREB1 as a key regulator of metabolic and stemness properties of PDAC.Significance:CircRREB1 stimulates PGK1 to induce glycolysis and activates the Wnt/β-catenin signaling pathway to maintain stemness in pancreatic cancer, indicating the potential of circRREB1 as a biomarker and therapeutic target.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal tumor with limited treatment options and poor patient survival. Circular RNAs (circRNA) play crucial regulatory roles in the occurrence and development of various cancers, including PDAC. In this study, using circRNA sequencing of diverse PDAC samples, we identified circRREB1 as an oncogenic circRNA that is significantly upregulated in PDAC and is correlated with an unfavorable patient prognosis. Functionally, loss of circRREB1 markedly inhibited glycolysis and stemness, whereas elevated circRREB1 elicited the opposite effects. Mechanistically, circRREB1 interacted with PGK1, disrupting the association between PTEN and PGK1 and increasing PGK1 phosphorylation to activate glycolytic flux. Moreover, circRREB1 promoted WNT7B transcription by directly interacting with YBX1 and facilitating its nuclear translocation, consequently activating the Wnt/β-catenin signaling pathway to maintain PDAC stemness. Overall, these results highlight circRREB1 as a key regulator of metabolic and stemness properties of PDAC.Significance:CircRREB1 stimulates PGK1 to induce glycolysis and activates the Wnt/β-catenin signaling pathway to maintain stemness in pancreatic cancer, indicating the potential of circRREB1 as a biomarker and therapeutic target.
- Open Access
- 3 November 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-15
m6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis
N6-methyladenosine (m 6 A) modification has emerged as a common chemical modification in epigenetic regulation. However, whether this m 6 A modification is involved in glycolysis metabolism in pancreatic ductal adenocarcinoma (PDAC) remains elusive. Multiomics integration strategies, including metabolomics, m 6 A-seq and transcriptome sequencing, were utilized to evaluate the associations between m 6 A modifications and key processes of glucose metabolism in PDAC. Spontaneous PDAC mice (LSLKras G12D/+ , LSL-Trp53 R172H/+ , Pdx1-Cre; KPC) with FTO-conditional knockout and organoids were used to evaluate the effects of FTO stimulation on PDAC cell glycolysis and tumorigenesis. Series of in vivo and vitro functional analysis revealed that FTO promoted migratory capacity and glycolysis of PDAC cells. Mechanistically, FTO elevates the mRNA expression of the transcription factor C-Jun in a m 6 A-YTHDF2-dependent manner and further transcriptionally upregulates PFKM expression. Translational studies involving organoid models and xenograft tumor models revealed that the use of FTO inhibitors significantly suppressed PDAC growth. Our findings uncover that targeting the m 6 A-dependent FTO/C-Jun/PFKM glycolysis regulatory axis may be essential for the prevention and treatment of PDAC.
- 3 November 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-15
Open Accessm6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis
N6-methyladenosine (m 6 A) modification has emerged as a common chemical modification in epigenetic regulation. However, whether this m 6 A modification is involved in glycolysis metabolism in pancreatic ductal adenocarcinoma (PDAC) remains elusive. Multiomics integration strategies, including metabolomics, m 6 A-seq and transcriptome sequencing, were utilized to evaluate the associations between m 6 A modifications and key processes of glucose metabolism in PDAC. Spontaneous PDAC mice (LSLKras G12D/+ , LSL-Trp53 R172H/+ , Pdx1-Cre; KPC) with FTO-conditional knockout and organoids were used to evaluate the effects of FTO stimulation on PDAC cell glycolysis and tumorigenesis. Series of in vivo and vitro functional analysis revealed that FTO promoted migratory capacity and glycolysis of PDAC cells. Mechanistically, FTO elevates the mRNA expression of the transcription factor C-Jun in a m 6 A-YTHDF2-dependent manner and further transcriptionally upregulates PFKM expression. Translational studies involving organoid models and xenograft tumor models revealed that the use of FTO inhibitors significantly suppressed PDAC growth. Our findings uncover that targeting the m 6 A-dependent FTO/C-Jun/PFKM glycolysis regulatory axis may be essential for the prevention and treatment of PDAC.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression
Supplementary Materials and methods Supplementary Figures S1 to S17 Supplementary Tables S1 to S7
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression
Supplementary Materials and methods Supplementary Figures S1 to S17 Supplementary Tables S1 to S7
- 17 September 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (24) , 4246-4263
CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal tumor with limited treatment options and poor patient survival. Circular RNAs (circRNA) play crucial regulatory roles in the occurrence and development of various cancers, including PDAC. In this study, using circRNA sequencing of diverse PDAC samples, we identified circRREB1 as an oncogenic circRNA that is significantly upregulated in PDAC and is correlated with an unfavorable patient prognosis. Functionally, loss of circRREB1 markedly inhibited glycolysis and stemness, whereas elevated circRREB1 elicited the opposite effects. Mechanistically, circRREB1 interacted with PGK1, disrupting the association between PTEN and PGK1 and increasing PGK1 phosphorylation to activate glycolytic flux. Moreover, circRREB1 promoted WNT7B transcription by directly interacting with YBX1 and facilitating its nuclear translocation, consequently activating the Wnt/β-catenin signaling pathway to maintain PDAC stemness. Overall, these results highlight circRREB1 as a key regulator of metabolic and stemness properties of PDAC. Significance: CircRREB1 stimulates PGK1 to induce glycolysis and activates the Wnt/β-catenin signaling pathway to maintain stemness in pancreatic cancer, indicating the potential of circRREB1 as a biomarker and therapeutic target.
- 17 September 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (24) , 4246-4263
CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal tumor with limited treatment options and poor patient survival. Circular RNAs (circRNA) play crucial regulatory roles in the occurrence and development of various cancers, including PDAC. In this study, using circRNA sequencing of diverse PDAC samples, we identified circRREB1 as an oncogenic circRNA that is significantly upregulated in PDAC and is correlated with an unfavorable patient prognosis. Functionally, loss of circRREB1 markedly inhibited glycolysis and stemness, whereas elevated circRREB1 elicited the opposite effects. Mechanistically, circRREB1 interacted with PGK1, disrupting the association between PTEN and PGK1 and increasing PGK1 phosphorylation to activate glycolytic flux. Moreover, circRREB1 promoted WNT7B transcription by directly interacting with YBX1 and facilitating its nuclear translocation, consequently activating the Wnt/β-catenin signaling pathway to maintain PDAC stemness. Overall, these results highlight circRREB1 as a key regulator of metabolic and stemness properties of PDAC. Significance: CircRREB1 stimulates PGK1 to induce glycolysis and activates the Wnt/β-catenin signaling pathway to maintain stemness in pancreatic cancer, indicating the potential of circRREB1 as a biomarker and therapeutic target.